My interest in GTG is fairly small and I rarely get the chance to delve deep into the Ann’s so I’ll just ask the question here. Is the IBX deal dead or is it going through further regulatory red tape?
I note that their saliva test has just been approved but I’m unsure if that has any impact on our deal with them at all. Possibly just further genetic data to add to the overall profile with mutating variants? https://www.fda.gov/media/137773/download
I’m not on here often so apologies if this information has already been covered.
GTG Price at posting:
0.8¢ Sentiment: Hold Disclosure: Held
